Plant and Fungal Hallucinogens as Toxic and Therapeutic Agents
E. A. Carlini, Lucas O. Maia
Plant Toxins 2019 DOI: 10.1007/978-94-007-6728-7_6-2 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Hallucinogens Psychedelics Mental disorders Indole alkaloids Traditional medicine |
| Citations | 3 |
| Key findings | Hallucinogens of natural origin encompass diverse chemical classes with profound consciousness-altering effects, influenced by set and setting, and show potential both as models of mental disorders and as therapeutic agents. |
Abstract
This chapter aimed to provide an overview of the large number of hallucinogens of natural origin. Following a literature review, the following hallucinogens were selected for a detailed description that considered their essential chemical groups: indoleamines ( N,N -dimethyltryptamine, 5-methoxy- N,N -dimethyltryptamine, bufotenine, psilocybin, and ibogaine), phenylethylamines (mescaline), tropane alkaloids (atropine and scopolamine), cannabinoids (Δ^9-tetrahydrocannabinol), and a neoclerodane diterpenoid (salvinorin A). The following species were included as representative of each drug class: Mimosa tenuiflora , Psychotria viridis, Banisteriopsis caapi, Virola spp., Psilocybe spp., Tabernanthe iboga , Tabernaemontana spp., Lophophora spp., Trichocereus spp., Atropa belladonna , Brugmansia spp., Cannabis sativa , and Salvia divinorum , among others. In addition to psychopharmacological effects, this chapter aims to address the sociocultural and historical use of these hallucinogenic plants and mushrooms, along with the importance of both the set and the setting factors that affect the profound consciousness-altering effects of these compounds. Moreover, the use of animal models to predict the hallucinogenic properties of psychoactive plants and compounds and to investigate the mechanisms of action of psychodysleptic drugs is discussed. This chapter also attempts to establish a parallel between hallucinogens and endogenous neurotransmitters in humans, to compare the pharmacological and psychic action of these compounds, to evaluate hallucinogens’ ability to produce symptoms typical of certain mental disorders during their use, and to investigate the role of these compounds as therapeutic agents in several psychopathological conditions.
Citations in the library
Cited by 2
Cites 20
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology December 1, 2011
- Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies Journal of Psychopharmacology September 20, 2010
- The pharmacology of psilocybin Addiction Biology October 1, 2002
- Psilocybin – Summary of knowledge and new perspectives European Neuropsychopharmacology December 17, 2013
- REACTIONS TO PSILOCYBJN ADMINISTERED IN A SUPPORTIVE ENVIRONMENT The Journal of Nervous and Mental Disease December 1, 1963
and 15 more in the library